<DOC>
	<DOCNO>NCT00514397</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving temozolomide together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give temozolomide together radiation therapy work treat young patient pontine glioma .</brief_summary>
	<brief_title>Temozolomide Radiation Therapy Treating Young Patients With Pontine Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate time death patient newly diagnose diffuse pontine glioma , treat combination concomitant low-dose oral temozolomide radiotherapy , follow 12 month maintenance therapy extend low-dose temozolomide . - To assess quality life patient diffuse pontine glioma treatment . Secondary - To evaluate time tumor progression patient newly diagnose diffuse pontine glioma , treat combination concomitant low-dose oral temozolomide radiotherapy , follow 12 month maintenance therapy extend low-dose temozolomide . - To evaluate document toxicity administration temozolomide combine radiotherapy study toxicity associate chronic administration extend low-dose temozolomide schedule population group . - To document radiological response treatment MR imaging , available , functional imaging . OUTLINE : This multicenter study . - Chemoradiotherapy : Patients receive oral temozolomide daily 6 week ( 7 day per week ) concurrent radiotherapy ( 5 day per week ) . Patients without evidence disease progression proceed maintenance therapy begin least 4 week completion radiotherapy . - Maintenance therapy : Patients receive oral temozolomide daily day 1-21 . Treatment repeat every 4 week 1 year absence disease progression unacceptable toxicity . Quality life assess prior chemoradiotherapy prior course 1 adjuvant temozolomide prior every 3 subsequent course adjuvant temozolomide . After completion study therapy , patient follow every 8 week .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Newly diagnose diffuse intrinsic lesion center pons MRI No requirement histological diagnosis Clinical history &lt; 6 month Clinical finding must include least 1 3 follow sign brainstem tumor : Cranial nerve deficit Long tract sign Ataxia Exclusion criterion : Focal lesion brainstem Predominantly exophytic tumor PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status ( PS ) Lansky PS 60100 % ( unless reason decrease status direct result neurological involvement brainstem glioma ) Life expectancy &gt; 12 week Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Urea serum creatinine &lt; 1.5 time upper limit normal ( ULN ) Total direct bilirubin &lt; 1.5 time ULN AST ALT &lt; 3 time ULN Negative pregnancy test within 7 day prior administration temozolomide woman childbearing potential Exclusion criterion : Frequent vomit and/or medical condition , could interfere oral medication intake ( e.g. , partial bowel obstruction ) Pregnant breastfeed woman PRIOR CONCURRENT THERAPY : Exclusion criterion : Prior chemotherapy radiotherapy Other concurrent investigational drug Other concurrent chemotherapy , immunotherapy , biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>untreated childhood brain stem glioma</keyword>
</DOC>